The University of Southampton
University of Southampton Institutional Repository

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
The newly proposed term “metabolic dysfunction-associated fatty liver disease” (MAFLD) is replacing the old term “non-alcoholic fatty liver disease” (NAFLD) in many global regions, because it better reflects the pathophysiology and cardiometabolic implications of this common liver disease. The proposed change in terminology from NAFLD to MAFLD is not simply a single-letter change in an acronym, since MAFLD is defined by a set of specific and positive diagnostic criteria. In particular, the MAFLD definition specifically incorporates within the classification recognized cardiovascular risk factors. Although convincing evidence supports a significant association between both NAFLD and MAFLD, with increased risk of CVD morbidity and mortality, neither NAFLD nor MAFLD have received sufficient attention from the Cardiology community. In fact, there is a paucity of scientific guidelines focusing on this common and burdensome liver disease from cardiovascular professional societies. This Perspective article discusses the rationale and clinical relevance for Cardiologists of the newly proposed MAFLD definition.
Cardiovascular disease, Metabolic dysfunction-associated fatty liver disease (MAFLD), Non-alcoholic fatty liver disease (NAFLD), Pharmacotherapies, Risk factors
1475-2840
Zhou, Xiao-Dong
651ddd54-23ab-4d90-b432-0df1bd998df7
Cai, Jingjing
3f2f7ffa-583c-4b84-a620-23ad9f3c6c0b
Targher, Giovanni
404b0f39-7235-42b3-a296-6ef8fb4c9d3a
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Shapiro, Michael D.
f70722e2-b4b1-4e38-84db-fc49b3574b7d
Sung, Ki-Chul
828818bb-bdc7-4e81-9daf-148f06698a3e
Somers, Virend K.
e1c48ca9-c781-4614-a1a6-3238c342b978
Chahal, Anwar A.
8e34db98-83b0-48fb-8119-4a85302a8343
George, Jacob
2835e468-cde9-49c2-81cf-98cb2bf84a66
Chen, Li-Li
2c3b2850-dc99-4caa-a487-52067156ca55
Zhou, Yong
b39e90b6-f1c0-4d28-85a0-eee45a93a4f4
Zheng, Ming-Hua
cad3b216-821e-41e1-916a-db0ffb6ed188
CHESS-MAFLD consortium
Zhou, Xiao-Dong
651ddd54-23ab-4d90-b432-0df1bd998df7
Cai, Jingjing
3f2f7ffa-583c-4b84-a620-23ad9f3c6c0b
Targher, Giovanni
404b0f39-7235-42b3-a296-6ef8fb4c9d3a
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Shapiro, Michael D.
f70722e2-b4b1-4e38-84db-fc49b3574b7d
Sung, Ki-Chul
828818bb-bdc7-4e81-9daf-148f06698a3e
Somers, Virend K.
e1c48ca9-c781-4614-a1a6-3238c342b978
Chahal, Anwar A.
8e34db98-83b0-48fb-8119-4a85302a8343
George, Jacob
2835e468-cde9-49c2-81cf-98cb2bf84a66
Chen, Li-Li
2c3b2850-dc99-4caa-a487-52067156ca55
Zhou, Yong
b39e90b6-f1c0-4d28-85a0-eee45a93a4f4
Zheng, Ming-Hua
cad3b216-821e-41e1-916a-db0ffb6ed188

Sung, Ki-Chul, Somers, Virend K., Chahal, Anwar A., George, Jacob, Chen, Li-Li, Zhou, Yong and Zheng, Ming-Hua , CHESS-MAFLD consortium (2022) Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology, 21 (1), [270]. (doi:10.1186/s12933-022-01697-0).

Record type: Review

Abstract

The newly proposed term “metabolic dysfunction-associated fatty liver disease” (MAFLD) is replacing the old term “non-alcoholic fatty liver disease” (NAFLD) in many global regions, because it better reflects the pathophysiology and cardiometabolic implications of this common liver disease. The proposed change in terminology from NAFLD to MAFLD is not simply a single-letter change in an acronym, since MAFLD is defined by a set of specific and positive diagnostic criteria. In particular, the MAFLD definition specifically incorporates within the classification recognized cardiovascular risk factors. Although convincing evidence supports a significant association between both NAFLD and MAFLD, with increased risk of CVD morbidity and mortality, neither NAFLD nor MAFLD have received sufficient attention from the Cardiology community. In fact, there is a paucity of scientific guidelines focusing on this common and burdensome liver disease from cardiovascular professional societies. This Perspective article discusses the rationale and clinical relevance for Cardiologists of the newly proposed MAFLD definition.

Text
manuscript-R2 20221111 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (439kB)
Image
Figure 1 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (3MB)
Image
Figure 2 - Accepted Manuscript
Available under License Creative Commons Attribution.
Download (928kB)
Image
Figure 3-R1 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 4-R1 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 5 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 6 - Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
s12933-022-01697-0 (1) - Version of Record
Available under License Creative Commons Attribution.
Download (2MB)

Show all 8 downloads.

More information

Accepted/In Press date: 14 November 2022
Published date: 3 December 2022
Additional Information: Funding Information: GT is supported in part by grants from the School of Medicine, University of Verona, Verona, Italy. CDB is supported in part by the Southampton National Institute for Health and Care (NIHR) Biomedical Research Centre (IS-BRC-20004), UK. VKS is supported by NIH HL65176 and HL160619. MHZ is supported by National Natural Science Foundation of China (82070588), High Level Creative Talents from Department of Public Health in Zhejiang Province (S2032102600032). JG is supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206) and Project, ideas grants and investigator grants (APP2001692, APP1107178, APP1108422, APP1196492). Publisher Copyright: © 2022, The Author(s).
Keywords: Cardiovascular disease, Metabolic dysfunction-associated fatty liver disease (MAFLD), Non-alcoholic fatty liver disease (NAFLD), Pharmacotherapies, Risk factors

Identifiers

Local EPrints ID: 472718
URI: http://eprints.soton.ac.uk/id/eprint/472718
ISSN: 1475-2840
PURE UUID: 9f019642-e55f-4fd1-bd08-a5d43dfa86db
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 15 Dec 2022 17:43
Last modified: 17 Mar 2024 02:49

Export record

Altmetrics

Contributors

Author: Xiao-Dong Zhou
Author: Jingjing Cai
Author: Giovanni Targher
Author: Michael D. Shapiro
Author: Ki-Chul Sung
Author: Virend K. Somers
Author: Anwar A. Chahal
Author: Jacob George
Author: Li-Li Chen
Author: Yong Zhou
Author: Ming-Hua Zheng
Corporate Author: CHESS-MAFLD consortium

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×